Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients.
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
Lambertini, Matteo;Salomoni, Sharon;Ballestrero, Alberto;Del Mastro, Lucia;
2022-01-01
Abstract
Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lambertini 2022 j natl.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
678.73 kB
Formato
Adobe PDF
|
678.73 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
